E

EuBiologics Co Ltd
KOSDAQ:206650

Watchlist Manager
EuBiologics Co Ltd
KOSDAQ:206650
Watchlist
Price: 11 940 KRW 0.59%
Market Cap: 436.2B KRW
Have any thoughts about
EuBiologics Co Ltd?
Write Note

EuBiologics Co Ltd
Net Issuance of Debt

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

EuBiologics Co Ltd
Net Issuance of Debt Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Net Issuance of Debt CAGR 3Y CAGR 5Y CAGR 10Y
E
EuBiologics Co Ltd
KOSDAQ:206650
Net Issuance of Debt
-â‚©1.5B
CAGR 3-Years
18%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Celltrion Inc
KRX:068270
Net Issuance of Debt
-â‚©108B
CAGR 3-Years
-10%
CAGR 5-Years
5%
CAGR 10-Years
N/A
SK Bioscience Co Ltd
KRX:302440
Net Issuance of Debt
-â‚©95.5B
CAGR 3-Years
-326%
CAGR 5-Years
-57%
CAGR 10-Years
N/A
H
Hugel Inc
KOSDAQ:145020
Net Issuance of Debt
-â‚©2.1B
CAGR 3-Years
-8%
CAGR 5-Years
-43%
CAGR 10-Years
N/A
P
PharmaResearch Co Ltd
KOSDAQ:214450
Net Issuance of Debt
-â‚©7.1B
CAGR 3-Years
-67%
CAGR 5-Years
22%
CAGR 10-Years
N/A
Alteogen Inc
KOSDAQ:196170
Net Issuance of Debt
â‚©14.3B
CAGR 3-Years
N/A
CAGR 5-Years
58%
CAGR 10-Years
N/A
No Stocks Found

EuBiologics Co Ltd
Glance View

Market Cap
435.3B KRW
Industry
Biotechnology

EuBiologics Co., Ltd. engages in the research, development, and manufacture of biopharmaceutical products. The company is headquartered in Seoul, Seoul and currently employs 323 full-time employees. The company went IPO on 2017-01-24. The firm operates its business through two segments. The Vaccine segment manufactures and sells oral cholera vaccines. The Contract Research and Manufacturing Organization (CRMO) segment contracts, researches and manufactures biopharmaceuticals.

Intrinsic Value
17 631.48 KRW
Undervaluation 32%
Intrinsic Value
Price
E

See Also

What is EuBiologics Co Ltd's Net Issuance of Debt?
Net Issuance of Debt
-1.5B KRW

Based on the financial report for Sep 30, 2024, EuBiologics Co Ltd's Net Issuance of Debt amounts to -1.5B KRW.

What is EuBiologics Co Ltd's Net Issuance of Debt growth rate?
Net Issuance of Debt CAGR 3Y
18%

Over the last year, the Net Issuance of Debt growth was -25%. The average annual Net Issuance of Debt growth rates for EuBiologics Co Ltd have been 18% over the past three years .

Back to Top